Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2001

View Archived Issues

HIF-1 gene therapy product in clinical trial at U. of Pittsburgh Medical Center

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Enzon seeks FDA approval to clinically evaluate PEG-paclitaxel

Effects of CGP-3466 investigated in models of Parkinson's disease

DNA vaccine for malaria to be developed using PLASmin Complexes

BresaGen's lead anticancer compound E21R licensed to British Biotech

Viragen staged to begin U.S. clinical trials with Omniferon

Avanir begins late-stage clinical trials with new drug for neurological disorders

ETA receptor antagonists in various stages of clinical testing at Icos-Texas Biotechnology

Clinical trial commences for new antiangiogenic agent discovered by OSI and Pfizer

DU-127090 will be codeveloped by Lundbeck and Solvay for schizophrenia

Antiviral drugs acquired by Novartis from SB

Zeldox status in Europe updated by Pfizer

Elan/Incara partnership plans immediate entry into pivotal IBD trials for OP-2000

Global rights for novel Japanese antiviral agent granted to Lilly

Name change and recent TB4 research results announced by the former Alpha 1 Biomedicals

L-739758 preserves coronary flow reserve during progressive coronary arteriostenosis in pigs

BP-2-94: an H3 receptor agonist prodrug with an interesting antiinflammatory/antinociceptive profile

New potassium channel modulators synthesized and tested by NeuroSearch

Recent patent covers Lilly's new subtype-selective metabotropic glutamate receptor antagonists

Aventis team describes preparation and use of new cell adhesion, migration inhibitors

Chemokine receptor antagonists in GlaxoSmithKline portfolio

Novel antiinflammatory agents described by Bayer group

Inhibitors of PTP1B and their use covered in patent issued to Merck Frosst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...